COO — The Cooper Companies, Inc.
Is COO overbought or oversold? Here is the current MarketMoodz read.
The Cooper Companies, Inc. (COO) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Medical Instruments & Supplies) last closed at $60.72. The rating moved from Overbought to Oversold on November 17, 2026.
- Public ratingOversold (as of November 17, 2026)
- Last close$60.72
- Last changeMoved from Overbought to Oversold on November 17, 2026
- SectorHealthcare
- IndustryMedical Instruments & Supplies
See all oversold Healthcare stocks →
AI analysis
The Cooper Companies, Inc. combines a stable, recurring revenue franchise in contact lenses with growing exposure to specialty ophthalmic devices. Steady cash flow from consumables, a broad distribution footprint and an aging demographic backdrop underpin revenue resilience. Near-term catalysts include product rollouts, targeted M&A and margin recovery from operational efficiencies. Key vulnerabilities include competitive pricing pressure, regulatory/reimbursement shifts, supply‑chain cost volatility and exposure to discretionary healthcare demand. Social sentiment and recent public filing detail were not available in the provided data, creating some information uncertainty. On balance, the business profile supports moderate upside over the next month if execution and market conditions remain stable, while risks warrant continued monitoring of clinical, regulatory and competitive developments.
Key factors
- Recurring consumables business (contact lenses) provides steady, high-margin revenue and predictable cash flow
- Diversified product mix across contact lenses, eye-care solutions and ophthalmic surgical devices reduces single-market exposure
- Aging global population and rising prevalence of vision-corrective needs support long-term addressable market expansion
- Operational scale and established global distribution network enable efficient go-to-market and retailer/eye‑care channel relationships
- History of disciplined capital allocation, including buybacks and targeted M&A to expand specialty product portfolio
- Potential upside from new product rollouts and share gains in specialty/therapeutic ophthalmology segments
Risks
- Intense competition from large ophthalmic and medtech players leading to price pressure and share erosion
- Regulatory or reimbursement changes in major markets that could reduce procedure volumes or consumer access
- Sensitivity to consumer spending and cyclical demand for elective or nonurgent eye-care products
- Supply‑chain disruptions or component cost inflation that compress gross margins
- Foreign currency exposure and macroeconomic weakness in key international markets
- Litigation, product recalls or adverse clinical outcomes that can damage brand and incur remediation costs
- Limited visibility from lack of recent public filings/EDGAR updates in the provided dataset increases near-term information risk
Latest MarketMoodz coverage
See today's live rating, score and targets
Members see the live hourly rating for COO — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.